Novartis releases detail on asciminib's better-than-Bosulif CML data

8 December 2020

Swiss pharma giant Novartis (NOVN: VX) has presented detailed results on its investigational STAMP inhibitor asciminib’s comparison with Pfizer’s (NYSE: PFE) Bosulif (bosutinib) at the 62nd American Society of Hematology Annual Meeting & Exposition (ASH).

Asciminib showed a superior major molecular response (MMR) rate to Bosulif in patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine-kinase inhibitors (TKIs), in the Phase III ASCEMBL trial.

At 24 weeks, asciminib nearly doubled the MMR rate compared to Bosulif (bosutinib) according to data that, Novartis says, further reinforce the potential of asciminib to help patients with CML who suffer from intolerable side effects in later lines of therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK